drugset
drugset / Trial / NCT04166942

KD025 Hepatic Impairment Study With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment

NCT04166942 ↗

Phase 1 Completed 35 enrolled Kadmon, a Sanofi Company
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a study to characterize the pharmacokinetics, safety and tolerability of KD025 and KD025 metabolites in subjects with mild, moderate or severe hepatic impairment compared to healthy subjects with normal hepatic function.

Timeline

Start
2019-12-11
Primary completion
2022-06-06
Completion
2022-06-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Belumosudil Small molecule 200 mg Oral

Indications

No indication recorded.